CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03598998
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:39.238055+00:00
Published At: 2024-08-27T00:00:00+00:00
Record Updated At: 2025-06-26
Results Posted At: 2024-08-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Anaplastic Large Cell Lymphoma", "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Recurrent Anaplastic Large Cell Lymphoma", "Recurrent Angioimmunoblastic T-Cell Lymphoma", "Recurrent Enteropathy-Associated T-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Hepatosplenic T-Cell Lymphoma", "Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma", "Recurrent Mycosis Fungoides", "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Angioimmunoblastic T-Cell Lymphoma", "Refractory Enteropathy-Associated T-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Hepatosplenic T-Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Subcutaneous Panniculitis-Like T-Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-26"
protocolSection.identificationModule.nctId: "NCT03598998"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-08-27"

Study condition terms

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.